Kathy Lee-Sepsick Purchases 15,625 Shares of Femasys (NASDAQ:FEMY) Stock

Femasys Inc. (NASDAQ:FEMY) CEO Kathy Lee-Sepsick bought 15,625 shares of the stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Femasys Price Performance

Shares of NASDAQ:FEMY opened at $2.35 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98. Femasys Inc. has a one year low of $2.19 and a one year high of $22.20. The company has a market cap of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08. The firm has a fifty day moving average price of $3.77 and a two-hundred day moving average price of $7.42.

More Femasys News

Here are the key news stories impacting Femasys this week:

• Positive Sentiment: Femasys secured new U.S. and international patents covering FemBloc’s blended polymer, complementing existing delivery-system patents. The broader protection across the U.S., Europe, Japan, South Korea, Brazil, India and other markets could strengthen FemBloc’s competitive position and support future licensing or commercialization partnerships. FemBloc is already approved in Europe, the U.K. and New Zealand, although it remains investigational in the United States. Femasys Strengthens and Extends Global Patent Protection for FemBloc
• Positive Sentiment: Multiple company insiders purchased shares at $3.20, including the CEO, CFO, COO, CTO and Chief Medical Affairs executive. The purchases, totaling approximately $134,000, may be viewed as a vote of confidence by management, though the transactions are relatively small compared with the company’s potential capital needs. Femasys Insider Buying
• Neutral Sentiment: Femasys recently announced a $30 million private placement. The financing should provide substantial funds for operations and the ongoing FINALE pivotal trial, but investors need to assess the security terms and potential dilution before determining its net impact on existing shareholders. Femasys Completes $30 Million Private Placement Financing
• Negative Sentiment: FemBloc still requires successful completion of its U.S. pivotal trial and FDA approval. The company continues to face significant clinical, regulatory and commercialization risks, while Femasys remains unprofitable. Shares are trading well below their 50-day and 200-day moving averages, reflecting persistent investor caution.

Hedge Funds Weigh In On Femasys

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp boosted its holdings in Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after acquiring an additional 24,500 shares in the last quarter. Kovack Advisors Inc. purchased a new position in Femasys in the 4th quarter worth approximately $27,000. Osaic Holdings Inc. purchased a new position in Femasys in the 2nd quarter worth approximately $45,000. HRT Financial LP bought a new position in Femasys in the 4th quarter valued at approximately $30,000. Finally, Cetera Investment Advisers bought a new position in Femasys in the 4th quarter valued at approximately $36,000. Institutional investors own 65.27% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on FEMY. Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Femasys to a “hold” rating in a research note on Saturday, June 13th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $80.00.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.